P
Patricia Haney
Researcher at GlaxoSmithKline
Publications - 9
Citations - 3142
Patricia Haney is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Dabrafenib & Trametinib. The author has an hindex of 8, co-authored 9 publications receiving 2861 citations.
Papers
More filters
Journal ArticleDOI
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Anne-Marie Martin,Suzanne Swann,Patricia Haney,Beloo Mirakhur,Mary E. Guckert,Vicki L. Goodman,Paul B. Chapman +20 more
TL;DR: Dabrafenib significantly improved progression-free survival compared with dacarbazine, and skin-related toxic effects, fever, fatigue, arthralgia, and headache were uncommon in both groups.
Journal ArticleDOI
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Ademi Santiago-Walker,Robert C. Gagnon,Jolly Mazumdar,Michelle Casey,Georgina V. Long,Dirk Schadendorf,Keith T. Flaherty,Richard F. Kefford,Richard F. Kefford,Axel Hauschild,Patrick Hwu,Patricia Haney,Anne O'Hagan,Jennifer Carver,Vicki L. Goodman,Jeffrey J. Legos,Anne-Marie Martin +16 more
TL;DR: The lack of circulating, BRAF mutation–positive cfDNA is clinically significant for metastatic melanoma patients, and may be a prognostic marker for better disease outcome.
Journal ArticleDOI
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Beloo Mirakhur,Mary E. Guckert,R. Suzanne Swann,Patricia Haney,Vicki L. Goodman,Paul B. Chapman +19 more
TL;DR: Dabrafenib is a selective BRAF inhibitor with demonstrated efficacy in BRAF V600E-positive mutation in MM and the primary analysis of BREAK-3 (NCT01227889) compared progression-free s...
Journal ArticleDOI
Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Beloo Mirakhur,Mary E. Guckert,R. Suzanne Swann,Patricia Haney,Anne-Marie Martin,Danielle Ouellet,Kelly M. Grotzinger,Vicki L. Goodman,Paul B. Chapman +16 more
TL;DR: Dabrafenib demonstrated a significant improvement in PFS and ORR over DTIC with an acceptable safety profile and benefits in P FS and RR were observed in all subgroups evaluated.
Journal ArticleDOI
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites
Daniele Ouellet,Ekaterina Gibiansky,Cathrine Leonowens,Anne O'Hagan,Patricia Haney,Julie Switzky,Vicki L. Goodman +6 more
TL;DR: The population pharmacokinetics of dabrafenib, including changes over time and relevant covariates, were characterized based on results from four clinical studies using a nonlinear mixed effects model with a full covariate approach to predict metabolite exposure.